Cargando…

Chemotherapeutic Regimens and Chemotherapy-Free Intervals Influence the Survival of Patients with Recurrent Advanced Epithelial Ovarian Carcinoma: A Retrospective Population-Based Study

We aimed to evaluate factors influencing the outcomes of patients with platinum-sensitive recurrent epithelial ovarian carcinoma (EOC). Patients with advanced-stage EOC, who received debulking surgery and adjuvant chemotherapy for recurrence, were obtained from the National Health Insurance Research...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Hsin-Ying, Chiang, Chun-Ju, Chen, Yun-Yuan, You, San-Lin, Hsu, Heng-Cheng, Tang, Chao-Hsiun, Cheng, Wen-Fang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8296477/ https://www.ncbi.nlm.nih.gov/pubmed/34202996 http://dx.doi.org/10.3390/ijerph18126629

Ejemplares similares

Survival benefit of patients with early-stage ovarian carcinoma treated with paclitaxel chemotherapeutic regimens
por: Chen, Chien-An, et al.
Publicado: (2018)

Hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer
por: Chen, Wei-Chun, et al.
Publicado: (2022)

Analysis of the Efficacy of Multidrug Combination Chemotherapy Regimens for Osteosarcoma and the Management of Chemotherapeutic Reactions
por: Tian, Dawei, et al.
Publicado: (2022)

Trends in incidence and survival outcome of epithelial ovarian cancer: 30-year national population-based registry in Taiwan
por: Chiang, Ying-Cheng, et al.
Publicado: (2013)

Prognostic Influence of the Time Interval between Surgery and Chemotherapy in Epithelial Ovarian Cancer
por: Liu, Xiao-Dong, et al.
Publicado: (2018)

Exploration of chemotherapy-free regimen after multi-line chemotherapy-induced renal impairment in recurrent ovarian cancer: Case report and literature review
por: Zhang, Liu-ping, et al.
Publicado: (2023)

Retracted: Analysis of the Efficacy of Multidrug Combination Chemotherapy Regimens for Osteosarcoma and the Management of Chemotherapeutic Reactions
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2023)

The Impact of IDH1 Mutation and MGMT Promoter Methylation on Recurrence-Free Interval in Glioblastoma Patients Treated With Radiotherapy and Chemotherapeutic Agents
por: Kurdi, Maher, et al.
Publicado: (2021)

Ovarian cancer risk score predicts chemo-response and outcome in epithelial ovarian carcinoma patients
por: Lu, Hsiao-Yun, et al.
Publicado: (2020)

Impact of the Time Interval Between Primary Debulking Surgery and Start of Adjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer
por: Lin, Hao, et al.
Publicado: (2021)

Incidence of venous thromboembolism following the neoadjuvant chemotherapy regimen for epithelial type of ovarian cancer
por: Chavan, Devendra Manik, et al.
Publicado: (2017)

Cardiotoxicity by Anthracycline Regimen Chemotherapy Prolonged T Peak to T End Interval
por: Iqbal, Mohammad, et al.
Publicado: (2020)

Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study
por: Pignata, Sandro, et al.
Publicado: (2008)

Clinical relevance of cancer stem cell chemotherapeutic assay for recurrent ovarian cancer()
por: Howard, Candace M., et al.
Publicado: (2020)

Neoadjuvant chemotherapy followed by interval debulking surgery for advanced epithelial ovarian cancer: GOTIC-019 study
por: Nagao, Shoji, et al.
Publicado: (2023)

Metabolic interrogation as a tool to optimize chemotherapeutic regimens
por: Sandulache, Vlad C., et al.
Publicado: (2017)

Potential predictors for chemotherapeutic response and prognosis in epithelial ovarian, fallopian tube and primary peritoneal cancer patients treated with platinum-based chemotherapy
por: Jeerakornpassawat, Dhammapoj, et al.
Publicado: (2020)

Chemotherapy-free treatment of recurrent advanced ovarian cancer: myth or reality?
por: Marques, Cristiana, et al.
Publicado: (2023)

Interval between secondary cytoreductive surgery and adjuvant chemotherapy is not associated with survivals in patients with recurrent ovarian cancer
por: Jeong, Soo Young, et al.
Publicado: (2019)

Weekly Dose-Dense Paclitaxel and Triweekly Low-Dose Cisplatin: A Well-Tolerated and Effective Chemotherapeutic Regimen for First-Line Treatment of Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
por: Cheng, Min, et al.
Publicado: (2019)

Bleomycin Containing Chemotherapeutic Regimen Induced Acquired Partial Lipodystrophy
por: Tandon, Vishal R, et al.
Publicado: (2016)

A Systematic Review of Chemotherapeutic Regimens Used in Pancreatic Cancer
por: Awais, Nimra, et al.
Publicado: (2023)

The Effects of Chemotherapeutics on the Ovarian Cancer Microenvironment
por: Eckert, Mark A., et al.
Publicado: (2021)

Evolving Chemotherapy Free Regimens for Acute Promyelocytic Leukemia
por: Kulkarni, Uday, et al.
Publicado: (2021)

Oral metronomic chemotherapy for recurrent & refractory epithelial ovarian cancer: A retrospective analysis
por: Sharma, Aparna, et al.
Publicado: (2019)

Timing of interval debulking surgery and postoperative chemotherapy after neoadjuvant chemotherapy in advanced epithelial ovarian cancer: a multicenter real-world study
por: Liu, Xingyu, et al.
Publicado: (2023)

Tripterygium glycosides sensitizes cisplatin chemotherapeutic potency by modulating gut microbiota in epithelial ovarian cancer
por: Zhan, Xinlu, et al.
Publicado: (2023)

Impact of the time interval between primary or interval surgery and adjuvant chemotherapy in ovarian cancer patients
por: Farolfi, Alberto, et al.
Publicado: (2023)

Prognostic Factors of Early Stage Epithelial Ovarian Carcinoma
por: Hsieh, Shu-Feng, et al.
Publicado: (2019)

Impact of the Time Interval Between Primary Debulking Surgery and Start of Adjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer [Corrigendum]
Publicado: (2021)

Platinum resistant recurrence and early recurrence in a multi-centre cohort of patients undergoing interval cytoreductive surgery for advanced epithelial ovarian cancer
por: Bhatt, Aditi, et al.
Publicado: (2022)

Intraoperative intraperitoneal chemotherapy with cisplatin in epithelial ovarian cancer
por: Kim, Myung Joo, et al.
Publicado: (2012)

Oncologic Outcomes of Stage IIIA Colon Cancer for Different Chemotherapeutic Regimens
por: Lee, Yoo Sung, et al.
Publicado: (2012)

Targeting CD133 improves chemotherapeutic efficacy of recurrent pediatric pilocytic astrocytoma following prolonged chemotherapy
por: Xi, Guifa, et al.
Publicado: (2017)

Treatment of recurrent epithelial ovarian cancer
por: Pisano, Carmela, et al.
Publicado: (2009)

Treatment of Recurrent Epithelial Ovarian Cancer
por: Claussen, Carlota, et al.
Publicado: (2020)

Optimal number of neoadjuvant chemotherapy cycles prior to interval debulking surgery in advanced epithelial ovarian cancer: a systematic review and meta-analysis of progression-free survival and overall survival
por: Coada, Camelia Alexandra, et al.
Publicado: (2023)

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval
por: Kaye, S. B., et al.
Publicado: (2011)

Prediction of chemotherapeutic resistance in serous ovarian cancer with low-density custom microarray
por: Zhu, Hong-Lan, et al.
Publicado: (2020)

Timed adoptive T cell transfer during chemotherapy in patients with recurrent platinum-sensitive epithelial ovarian cancer
por: Verdegaal, Els M E, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0g1uudh51mbgorbtl0rglu405n